Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cabozantinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 11/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 3/20 | 1.00 |
| ▸ | AXL | P30530 | 12/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 4/20 | 1.00 |
| ▸ | MERTK | Q12866 | 3/20 | 1.00 |
| ▸ | FLT1 | P17948 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cabozantinib SCHEMBL29728791 | 1.00 | AXL (1.00) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL29351408 | 1.00 | AXL (1.00) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL18095042 | 0.99 | AXL (0.98) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL18097906 | 0.97 | AXL (0.94) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL18095040 | 0.96 | AXL (0.93) | AXLMETAURKBMERTKFLT1 | |
| SCHEMBL30692003 | 0.96 | AXL (0.93) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL29195419 | 0.95 | AXL (0.91) | AXLMETAURKBMERTKFLT1 | |
| SCHEMBL15872120 | 0.95 | AXL (0.90) | AXLMETAURKBMERTKFLT1 | |
| SCHEMBL30918289 | 0.95 | AXL (0.90) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL18097904 | 0.95 | AXL (0.90) | AXLMETAURKBMERTKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1007 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243165-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12227481-B2 | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | EXELIXIS, INC. (US) | 2025-02-18 | — | — | US | claimed |
| US-20240287002-A1 | METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE | EXELIXIS INC (US) | 2024-08-29 | — | — | US | claimed |
| US-20240279181-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS INC (US) | 2024-08-22 | — | — | US | claimed |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-08-06 | — | — | US | claimed |
| US-20240190825-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | BIOCON LIMITED (IN) | 2024-06-13 | — | — | US | claimed |
| US-20240156803-A1 | Method of Treating Cancer | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-16 | — | — | US | claimed |
| EP-4313048-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | Biocon Limited (IN) | 2024-02-07 | — | — | EP | claimed |
| US-20240010621-A1 | CRYSTALLINE SOLID FORMS OF SALTS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USE | EXELIXIS, INC. | 2024-01-11 | — | — | US | claimed |
| US-11731941-B2 | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | EXELIXIS, INC. | 2023-08-22 | — | — | US | claimed |
| US-20140121239-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA | EXELIXIS, INC. (US) | 2014-05-01 | — | — | US | claimed |
| US-20140057943-A1 | Method of Treating Cancer | EXELIXIX, INC. (US) | 2014-02-27 | — | — | US | claimed |
| WO-2013166296-A1 | A DUAL MET - VEGF MODULATOR FOR TREATING OSTEOLYTIC BONE METASTASES | EXELIXIS, INC. (US) | 2013-11-07 | — | — | WO | claimed |
| EP-2387563-B1 | MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | claimed |
| US-20120035212-A1 | (L)-Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2012-02-09 | — | — | US | claimed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | claimed |
| EP-2409704-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2012-01-25 | — | — | EP | claimed |
| EP-2387563-A1 | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer | Exelixis, Inc. (US) | 2011-11-23 | — | — | EP | claimed |
| US-20110252754-A1 | HORSEBACK RIDING SPUR MECHANISM | COOK KARL | 2011-10-20 | — | — | US | claimed |
| WO-2010083414-A1 | MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUIN0LIN-4-YL] OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEROF FOR THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2010-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156803-A1 | Method of Treating Cancer | MET, HGF, ACP3 | MET 1/4885KDR 8/4885AXL 2179/4885 |
| US-20250243165-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, ME1 | MET 361/4885KDR 4344/4885AXL 3371/4885 |
| US-20120022065-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885KDR 5/4885AXL 241/4885 |
| US-20240190825-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | PDK1, PDHB, MPC2 | MET 197/4885KDR 351/4885AXL 612/4885 |
| US-20240010621-A1 | CRYSTALLINE SOLID FORMS OF SALTS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USE | RCC1, RCC2, CALU | MET 707/4885KDR 3558/4885AXL 1093/4885 |
| US-11731941-B2 | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | RCC1, RCC2, CALU | MET 702/4885KDR 3521/4885AXL 1101/4885 |
| US-20240279181-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, ME1 | MET 361/4885KDR 4344/4885AXL 3371/4885 |
| US-20120035212-A1 | (L)-Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | MDH1, MDH2, SLC25A11 | MET 350/4885KDR 4302/4885AXL 3650/4885 |
| US-20140121239-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA | RET, MET, KIF5B | MET 2/4885KDR 19/4885AXL 1207/4885 |
| US-20140057943-A1 | Method of Treating Cancer | MET, HGF, ACP3 | MET 1/4885KDR 8/4885AXL 2179/4885 |
| US-12227481-B2 | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | RCC1, RCC2, CALU | MET 707/4885KDR 3558/4885AXL 1093/4885 |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | MET 3718/4885KDR 2827/4885AXL 4696/4885 |
| US-20240287002-A1 | METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE | NQO2, AURKA, CDC25B | MET 369/4885KDR 430/4885AXL 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.